Navigation Links
Marshall Edwards Adds $2 Million in Private Placement
Date:12/29/2011

SAN DIEGO, Dec. 29, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has reached a definitive agreement with its majority shareholder, Novogen Limited, to sell common stock in a private placement for gross proceeds of $2 million, before deducting fees and expenses of the offering, through the sale of approximately 1.94 million shares of common stock. The offering is expected to close by tomorrow, December 30, 2011, subject to certain customary closing conditions.

The net proceeds from the offering will be used to continue development of Marshall Edwards' lead oncology drug candidates, including the submission of an Investigational New Drug (IND) application for ME-344 in the first quarter of 2012 and the completion of a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors in the second quarter of 2012.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Marshall Edwards, Inc. nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143. The Company initiated a Phase I clin
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
2. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
3. Marshall Edwards to Host Annual Meeting of Stockholders
4. Marshall Edwards Receives Positive Response From NASDAQ
5. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
6. Marshall Edwards Announces Private Placement
7. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
8. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
9. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
10. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
11. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Abaxis, Inc. (NasdaqGS: ... instrumentation and consumables to the medical, research and veterinary ... and Chief Executive Officer, will present at the CL ... on Tuesday, September 9, 2014 at 12:30 p.m. ET. ... Place Hotel in New York City ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has ... Tissue Repair Devices Market 2014-2018" report to their ... mass of cells that connect, support, or surround bones. ... as tendons, ligaments, cartilage, fascia, and other fibrous tissues. ... tissues with age result in wear and tear in ...
(Date:8/28/2014)... WILMINGTON, Del. , Aug. 28, 2014  Rigrodsky & Long, ... shares of Lannett Company, Inc. (NYSE: LCI )? , ... between September 10, 2013 and July 16, 2014, inclusive? , ... Inc.? , Do you want to discuss your rights? ... former Special Assistant United States Attorney, Timothy J. MacFall , ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... BELLEVUE, Wash., Feb. 29, 2012 Talyst , a ... the 8th annual 340B Coalition Winter Conference. The new tool ... The 340B Savings Calculator lets health systems ... http://www.340bsavings.com/ . "Talyst is dedicated to ensure ...
... today announced that it has dosed the first patient ... cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in pediatric ... These three cancers represent approximately 50% of all cancers ... with advanced cancers who have failed current therapy will ...
Cached Medicine Technology:Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma 2Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma 3
(Date:8/30/2014)... 30, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Removecomplaints.net, a ... management industry, has announced to offer guarantee of results ... to offer this guarantee because of its tremendous track ... 200 clients from all over the world and received ... good job. , On being asked about the ...
(Date:8/30/2014)... When a prominent bank reveals a successful ... Wednesday, August 27th, when news began surfacing about the ... Co and at least one other bank. But when ... attacks on seven prominent banks , everyone starts thinking about ... the buzz quickly goes viral. Bloomberg followed up on ...
(Date:8/30/2014)... August 30, 2014 Zensah®, the leader in ... Compression Leg Sleeve . The camo sleeves are the first ... collection. The camo line includes classic colors like army ... , Known as tibial stress syndrome, shin splints cause ... lower leg. Swollen and irritated muscles, stress fractures, or over ...
(Date:8/30/2014)... August 30, 2014 Celebrating its ... that educates Americans about the fact that millions ... from alcohol and drug addiction and mental health ... with treatment providers, prevention programs and other community ... families, workplaces and neighborhoods. The rallying theme ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Removecomplaints.net Announces Guaranteed Complaints Removal Services 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 3Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 4Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 5Health News:Camo Compression Leg Sleeves Provide Shin Splint Relief for Runners 2Health News:September is National Recovery Month: What the Connecticut Community for Addiction Recovery (CCAR) Wants You to Know 2Health News:September is National Recovery Month: What the Connecticut Community for Addiction Recovery (CCAR) Wants You to Know 3
... the secret behind inflorescence, the system that governs how ... , ,Using mathematical models and molecular genetics, the team ... together to create inflorescences as different as Forget-Me-Not and ... that provides an explanation for the diversity of inflorescences ...
... in the capital on Saturday. ,The Nigah ... directed by many international directors. The films will be followed ... aim of the programme is to give voice to the ... Penal Code (IPC) is still in existence. Section 377 criminalizes ...
... distribute about 100,000 decks of playing cards with information ... migrant workers in July, Xinhua/People's Daily reports. ... at construction sites and railway stations in Beijing, Shanghai, ... the Chinese Foundation for the Prevention of STDs and ...
... to fighting global warming, the 2007 graduates of the Yale ... that sequester carbon dioxide or develop renewable energy in ... as they travel to commencement on Memorial Day. ... to offset 330 tons of carbon dioxide, which is equivalent ...
... genetically engineered mice to lack an enzyme called Cdk5 in ... which made the animal more adept at learning and quicker ... to other normal rats. ,"Its pretty rare that ... cognitive implications," Nature magazine quoted senior study author Dr. James ...
... mouse when working on the computer can lead to a ... mouse arm, warn experts . ,"Tingling, numbness, and ... signs of overstressing of the tendons and nerves due to ... of Nerve Doctors (BVDN). ,"Constant clicking with the ...
Cached Medicine News:Health News:Gay Film Festival Begins in Delhi 2Health News:Yale F&ES Graduation to Offset Gas Linked to Global Warming 2Health News:Scientist Found New Mechanism for Brain Learning 2
For the quantitative determination of Glucose in serum. Endpoint Reaction Product measured at 520 nm. Linearity: 500 mg/dl....
Inorganic phosphorus reagent is used for the quantitative determination of inorganic phosphorus in human serum....
Gamma Glutamyl Transferase reagent is used for the quantitative determination of Gamma -GT in human serum....
For the kinetic quantitative determination of g-Glutamyl Transferase in serum for manual and/or automated procedures....
Medicine Products: